EDITOR—Our article merely points to an inefficiency in drug development that seems to be driven by commercial imperatives, and as the targets are phoney diagnoses no advance is made. If we merely promote new indications for old drugs and dump existing compounds when they lose their patents is it surprising that depression and anxiety remain such major causes of morbidity?

Weeks is right to assert that …